Santen Pharmaceutical updates share buyback program status

Santen Pharmaceutical Co., Ltd. announced an update on its share buyback program. For the period from October 1, 2025, to October 31, 2025, the company repurchased 3,071,200 common shares totaling JPY 4,765,731,250 through open-market transactions.

This latest acquisition contributes to the cumulative buyback initiated following the Board of Directors' resolution on May 13, 2025. As of October 31, 2025, Santen has repurchased a total of 19,646,600 common shares, amounting to JPY 31,663,080,500.

The initial resolution approved the repurchase of up to 19,800,000 shares, representing 5.8% of the total outstanding shares (excluding treasury shares), with a maximum aggregate value of JPY 35.0 bn. The buyback period is set to conclude on November 5, 2025. Santen aims to contribute to "Happiness with Vision" globally by focusing on eye health through its products and services.